The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas.

Holte, H; Davies, C D; Kvaløy, S; Smeland, E B; Foss-Abrahamsen, A; Kaalhus, O; Marton, P F; Godal, T

Holte, H; Davies, C D; Kvaløy, S; Smeland, E B; Foss-Abrahamsen, A; Kaalhus, O; Marton, P F; Godal, T.

Int J Cancer ; 39(5): 590-4, 1987 May 15.

Article in En | MEDLINE | ID: mdl-3106247

Subject(s)

B-Lymphocytes/classification; Lymphoma, Non-Hodgkin/immunology; Antibodies, Monoclonal; Antigens, Surface/immunology; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; DNA/biosynthesis; Female; Flow Cytometry; Humans; Lymphoma, Non-Hodgkin/drug therapy; Lymphoma, Non-Hodgkin/mortality; Male; Middle Aged; Prognosis; Receptors, Immunologic/analysis; Receptors, Interleukin-2; Statistics as Topic

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / B-Lymphocytes Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Int J Cancer Year: 1987 Type: Article

Search on Google

XML

PubMed Links